常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.69/-0.55
|
|
企业价值
779.04M
|
| 资产负债 |
|
每股账面净值
-0.60
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
57.56M
|
|
每股收益
0.40
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/07 20:26 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States. |

6.04 
